USPTO Examiner ARIANI KADE - Art Unit 1651

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19207422ASPERGILLUS FUMIGATUS FOR DEGRADING SOIL MICROPLASTICS AND APPLICATION THEREOFMay 2025December 2025Allow720NoNo
18934153FILAMENTOUS FUNGUS AND USE THEREOF IN GAS METABOLISMOctober 2024April 2025Allow510NoNo
18850239USE OF FUSARIUM BRACHYGIBBOSUM IN PRODUCTION OF MYCELIAL PROTEINSeptember 2024November 2025Allow1411NoNo
18785085PROBIOTICS COMPLEX COMPOSITION WITH IMMUNOMODULATORY AND IMMUNE HOMEOSTASIS PROPERTYJuly 2024February 2026Allow1910NoNo
18749228Microbial Lysozyme for use in the Treatment of Irritable Bowel Syndrome or Inflammatory Bowel DiseaseJune 2024February 2026Allow2011NoNo
18744950ALKALINE PHOSPHATASE FORMULATIONSJune 2024August 2025Allow1410NoNo
18735829Methods and Compositions for the Treatment of Cytoplasmic Glycogen Storage DisordersJune 2024October 2025Abandon1601NoNo
18675254PROBIOTIC COMPOSITION FOR IMPROVING SOY PROTEIN PROTEOLYSIS AND AMINO ACID PRODUCTION ACTIVITYMay 2024January 2026Allow2010NoNo
18673024BACTERIOPHAGES FOR TREATMENT OF TUBERCULOSISMay 2024December 2025Allow1811YesNo
18654969METHOD FOR PREPARING CULTURES OF LACTIC ACID BACTERIAMay 2024November 2025Allow1911NoNo
18649162MICROBIAL FERMENTATION METHODS AND COMPOSITIONSApril 2024September 2025Allow1720NoNo
18628247Distributed Systems for the Efficient Production and Use of Microbe-Based CompositionsApril 2024March 2025Allow1111NoNo
18591288METHOD AND COMPOSITIONS FOR INHIBITING OR PREVENTING ADVERSE EFFECTS OF ORAL ANTIBIOTICSFebruary 2024April 2025Abandon1310NoNo
18440808METHODS FOR ENHANCING IMMUNE CHECKPOINT BLOCKADE THERAPY BY MODULATING THE MICROBIOMEFebruary 2024January 2025Allow1121YesNo
18432324ANTIMICROBIAL HEVAMINE A-RELATED COMPOSITIONS AND METHODSFebruary 2024December 2024Allow1011YesNo
18427867Method of Alleviating Obsessive Compulsive Disorder Symptoms by Use of a Multi-Strain Probiotic FormulationJanuary 2024March 2026Allow2510YesNo
18419725COMPOSITION OF STIMULATING IMMUNITY COMPRISING LACTOBACILLUS RHAMNOSUS LM1019 AND STARTER STRAINSJanuary 2024December 2025Allow2310NoNo
18417268Anaerobic Blood Storage and Pathogen Inactivation MethodJanuary 2024March 2025Allow1410NoNo
18411888MULTIUSE, ENZYMATIC DETERGENT AND METHODS OF STABILIZING A USE SOLUTIONJanuary 2024November 2024Allow1010YesNo
18534962MICROBIOME PROTECTION FROM ORAL ANTIBIOTICSDecember 2023December 2024Allow1210NoNo
18513267ACCELERATED DIRECTED EVOLUTION OF MICROBIAL CONSORTIA FOR THE DEVELOPMENT OF DESIRABLE PLANT PHENOTYPIC TRAITSNovember 2023July 2025Allow2020NoNo
18493262AGENT FOR USE IN THE CASE OF FRUCTOSE INTOLERANCEOctober 2023October 2025Abandon2311NoNo
18485872COMPOSITIONS AND METHODS FOR C. DIFFICILE TREATMENTOctober 2023August 2024Allow1010NoNo
18478368COLLAGENASE FORMULATIONS AND METHODS OF PRODUCING THE SAMESeptember 2023January 2025Allow1620NoNo
18459977LACTOBACILLUS PLANTARUM BNT_G401 STRAIN AND USE THEREOFSeptember 2023March 2026Abandon3110NoNo
18448948Biological Control Method For Ciliate DiseaseAugust 2023March 2026Allow3120NoNo
18447387DISTRIBUTED SYSTEMS FOR THE EFFICIENT PRODUCTION AND USE OF MICROBE-BASED COMPOSITIONSAugust 2023December 2023Allow410NoNo
18263992COMPOSITION FOR THE NUTRITION OR DRINK OF A NON-HUMAN ANIMALAugust 2023March 2026Allow3110NoNo
18226559PROTEINASE-FREE COATINGS FOR COLONY PASSAGINGJuly 2023August 2024Allow1310NoNo
18217743COMPOSITIONS AND METHODS FOR TREATMENT OF SKIN-RELATED DISEASES AND PROMOTING DERMATOLOGICAL HEALTHJuly 2023June 2025Allow2320NoNo
18268927A METHOD FOR PREPARING GINSENOSIDE PREPARATION BY BIOLOGICAL ENGINEERING TECHNOLOGYJune 2023February 2026Allow3220NoNo
18210901MICROORGANISMS AND ARTIFICIAL ECOSYSTEMS FOR THE PRODUCTION OF PROTEIN, FOOD, AND USEFUL CO-PRODUCTS FROM C1 SUBSTRATESJune 2023April 2025Allow2220YesNo
18328874LIQUID SPORULATION METHOD AND SPORULATION BROTHJune 2023October 2024Allow1730YesNo
18326267DEVELOPMENT OF AMYLOGLUCOSIDASE AS A MEDICINAL FOOD OR DIETARY SUPPLEMENTMay 2023September 2024Allow1510YesNo
18200557Methods and Compositions for the Treatment of Steatosis-Associated DisordersMay 2023August 2024Allow1510NoNo
18193086USE OF PLATELET RICH PLASMA COMPOSITION IN THE TREATMENT OF CARDIAC CONDUCTION ABNORMALITIESMarch 2023September 2024Abandon1710NoNo
18126459SYSTEMS AND METHODS FOR GROWING A BIOFILM OF PROBIOTIC BACTERIA ON SOLID PARTICLES FOR COLONIZATION OF BACTERIA IN THE GUTMarch 2023April 2025Allow2520NoNo
18184254COMPOSITION FOR INHIBITING TRYPSIN ACTIVITY CONTAINING AS ACTIVE INGREDIENT BACTERIUM BELONGING TO GENUS PARAPREVOTELLAMarch 2023January 2026Allow3411NoNo
18172021ENHANCED CAFFEINATED BEVERAGE COMPOSITIONFebruary 2023October 2023Allow810NoNo
18170644CELLULAR-BASED METHOD FOR DETERMINING THE POTENCY OF DEFIBROTIDEFebruary 2023January 2026Allow3510NoNo
18163648METHOD AND COMPOSITIONS FOR INHIBITING OR PREVENTING ADVERSE EFFECTS OF ORAL ANTIBIOTICSFebruary 2023February 2024Allow1310NoNo
18159934METHODS OF SYNERGISTIC TREATMENT OF CANCERJanuary 2023May 2024Allow1610YesNo
18016904MICROBIOLOGICAL PROCESS FOR THE PREPARATION OF URSOCHOLIC ACIDJanuary 2023December 2025Abandon3410NoNo
18096853ADENO-ASSOCIATED VIRUS FORMULATIONSJanuary 2023July 2024Allow1921YesNo
17997959LONG-LIVING, THERMOTOLERANT YEAST AND USE THEREOF IN PRODUCING A FERMENTED BEVERAGENovember 2022November 2024Allow2411YesNo
18049791MICROBIOME PROTECTION FROM ORAL ANTIBIOTICSOctober 2022September 2023Allow1110NoNo
17967840BIPOLARIS YAMADAE (Y. NISIK.) SHOEMAKER, AND SCREENING AND IDENTIFICATION METHOD THEREFOR AND USE THEREOFOctober 2022December 2025Allow3811YesNo
17962608METHODS OF TREATMENT OF CANCER BY CONTINUOUS INFUSION OF COENZYME Q10October 2022February 2026Allow4031NoNo
17995135COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY DISEASES OF DIGESTIVE SYSTEM OR COLITIS, COMPRISING REOVIRUS AS ACTIVE INGREDIENTSeptember 2022February 2026Abandon4111NoNo
17891810COMPOSITION AND METHODS FOR REDUCING CORN-ON-CORN YIELD PENALTYAugust 2022December 2023Allow1610NoNo
17798882BACTERIAL STRAINS, THE COMPOSITIONS THEREOF AND USE THEREOF IN A METHOD FOR THE TREATMENT OF VITAMIN D DEFICIENCY, AND DISORDERS ASSOCIATED THEREWITHAugust 2022July 2025Allow3611YesNo
17884346THEACRINE-BASED SUPPLEMENT AND METHOD OF USE THEREOF IN A SYNERGISTIC COMBINATION WITH CAFFEINEAugust 2022May 2023Allow910NoNo
17818668Anaplerotic Oil Production In MicrobialsAugust 2022February 2024Abandon1811NoNo
17796315A NOVEL STRAIN OF LACTOBACILLUS REUTERI LM1071 SEPARATED FROM BREAST MILK,AND COMPOSITION FOR RELIEVING PREMENSTRUAL SYNDROME COMPRISING THE STRAIN OR ITS CULTURE FLUIDJuly 2022August 2025Abandon3710NoNo
17873504METHODS OF GENERATING, REPAIRING AND/OR MAINTAINING CONNECTIVE TISSUE IN VIVOJuly 2022October 2024Allow2631NoNo
17814739MICROBIAL FERMENTATION METHODS AND COMPOSITIONSJuly 2022February 2024Allow1811YesNo
17814314METHODS FOR ENHANCING IMMUNE CHECKPOINT BLOCKADE THERAPY BY MODULATING THE MICROBIOMEJuly 2022January 2025Allow3012YesNo
17793942Use of a defoamer for maintaining dispersed morphology in submerged fungal fermentationJuly 2022August 2024Allow2521YesNo
17862028ACCELERATED DIRECTED EVOLUTION OF MICROBIAL CONSORTIA FOR THE DEVELOPMENT OF DESIRABLE PLANT PHENOTYPIC TRAITSJuly 2022July 2023Allow1210NoNo
17758150SUCROSE NEGATIVE STREPTOCOCCUS THERMOPHILUS FOR USE IN PREPARATION OF FERMENTED PRODUCTSJune 2022October 2025Allow3911NoNo
17758212LACTOBACILLUS FERMENTUM STRAIN, AND COMPOSITION FOR PREVENTING OR TREATING METABOLIC DISEASES, COMPRISING SAMEJune 2022August 2025Allow3811YesNo
17806303SYNERGISTIC CELLULASE-SURFACTANT INTERACTIONS FOR DEGRADATION OF BACTERIAL CELLULOSEJune 2022August 2023Allow1410YesNo
17784055METHOD FOR PREPARING CULTURES OF LACTIC ACID BACTERIAJune 2022January 2024Allow1911YesNo
17805753ANTIMICROBIAL HEVAMINE A-RELATED COMPOSITIONS AND METHODSJune 2022January 2024Allow1911YesNo
17782236Method for obtaining chitin and/or chitosan using two enzymatic hydrolysesJune 2022January 2026Abandon4320NoNo
17628811COMPOSITION FOR PREVENTING, TREATING, OR AMELIORATING VIRAL INFECTION DISEASE, CONTAINING A COMPLEX OF ENDOPLASMIC RETICULUM (ER) STRESS INHIBITOR AND REACTIVE OXYGEN SPECIES SCAVENGER AS ACTIVE INGREDIENTSMay 2022September 2025Allow4420YesNo
17778816HYALURONIDASE COMPOSITIONS AND METHODS OF USING SAME TO TREAT CELLULITEMay 2022November 2025Abandon4211NoNo
17776529Fermentation fungal substance of Astragalus membranaceus/Paecilomyces cicadae and its useMay 2022September 2023Allow1611YesNo
17773391COMPOSITION COMPRISING BOTULINUM TOXIN OR SALT THEREOF FOR INCREASING ENDOMETRIAL BLOOD FLOW RATEApril 2022November 2025Allow4221YesNo
17772359METHOD FOR PREPARING CHONDROITIN SULFATE OLIGOSACCHARIDES WITH C5 PROTEIN TARGETING PROPERTY, AND APPLICATION THEREOFApril 2022August 2025Abandon3911NoNo
17769125METHODS OF PROMOTING SCFA PRODUCTION BY GUT MICROBIOTAApril 2022July 2025Allow3911NoNo
17717678ROSEBURIA HOMINIS HGM001 ISOLATE AND USE THEREOFApril 2022June 2024Allow2620NoNo
17716939BACTERIOPHAGES FOR TREATMENT OF TUBERCULOSISApril 2022February 2024Allow2211YesNo
17767181COMPOSITION FOR IMPROVING RESPIRATORY DISEASES USING LACTOBACILLUS PLANTARUM STRAINApril 2022April 2025Allow3610NoNo
17766959YEAST FOR THE TREATMENT OF ALLERGYApril 2022November 2024Allow3120YesNo
17754430NOVEL SKIN CARE COMPOSITIONApril 2022November 2025Abandon4311NoNo
17761490USE OF MICROORGANISM TO IMPROVE PLANT PRODUCTIVITY OF SOILMarch 2022February 2024Allow2321NoNo
17696959Bifidobacterium Breve capable of relieving rheumatoid arthritis and application thereofMarch 2022March 2025Allow3611NoNo
17690879COMPOSITIONS AND METHODS FOR PROMOTING A HEALTHY MICROBIAL FLORA IN A MAMMALMarch 2022October 2024Allow3131YesNo
17686466DIGITAL MICROBIOLOGYMarch 2022December 2023Allow2111NoNo
17640296MICROORGANISM HAVING HIGH ABILITY TO DEGRADE OIL AT LOW TEMPERATUREMarch 2022September 2025Allow4221YesNo
17639161BACTERIAL OIL TREATMENT COMPOSITION FOR HANDLING A DECOMMISSIONED OIL CABLEFebruary 2022March 2024Allow2411YesNo
17639226ALLERGEN DETECTION MARKER AND ALLERGEN DETECTION METHOD USING SAMEFebruary 2022August 2025Allow4111NoNo
17635991PRODUCTION OF MONOACYL MELFebruary 2022January 2025Allow3510YesNo
17630450METHODS AND COMPOSITIONS FOR CONTROLLING OR REDUCING PESTSJanuary 2022February 2025Allow3621YesNo
17629149FAECALIBACTERIUM PRAUSNITZII AND CHRISTENSENELLA BACTERIAL STRAINS FOR THE TREATMENT AND PREVENTION OF BOWEL INFLAMMATIONJanuary 2022August 2024Abandon3101NoNo
17576733COMPOSITIONS AND METHODS OF IMPROVING RUMINANT PERFORMANCEJanuary 2022August 2024Allow3121YesNo
17623936Bifidobacterium breve CCFM1025, Food Fermented Thereby and Application ThereofDecember 2021June 2025Abandon4111NoNo
17559006Application of Dubosiella Newyorkensis in Prolonging Lifespan and Anti-AgingDecember 2021December 2024Abandon3610NoNo
17618681Bacillus Thuringiensis StrainDecember 2021November 2024Abandon3501NoNo
17545777MEDICINAL VAGINAL LACTOBACILLUS COCKTAILDecember 2021March 2025Allow4021YesNo
17543407TREATMENT FOR AIRWAY CAST OBSTRUCTIONDecember 2021May 2024Allow2920YesNo
17537714Production of 2-Hydroxyacyl-CoAs and Derivatives ThereofNovember 2021March 2025Allow4011NoNo
17614982GABA-PRODUCING CULTURABLE BACTERIA AND USE FOR IMPROVING HEALTHNovember 2021June 2025Allow4321YesNo
17455578COMPOSITIONS AND METHODS COMPRISING BACTERIA FOR IMPROVING BEHAVIOR IN NEURODEVELOPMENTAL DISORDERSNovember 2021February 2023Allow1510YesNo
17524923AIRWAY MEDICAMENTSNovember 2021March 2023Allow1641YesNo
17525759SUBCUTANEOUS ADMINISTRATION OF ADAMTS13November 2021May 2023Allow1810NoNo
17518810CONIOTHYRIUM MINITANS FOR PROTECTION OF CULTIVATED PLANTS FROM ATTACKS BY FUNGAL PATHOGENS BELONGING TO THE GENUS PHOMA SPP. OR VERTICILLIUM SPP.November 2021September 2023Abandon2210NoNo
17517410Microbial Lysozyme for use in the Treatment of Irritable Bowel Syndrome or Inflammatory Bowel DiseaseNovember 2021March 2024Allow2811YesNo
17604485FUNGAL STRAINS, PRODUCTION AND USES THEREOFOctober 2021August 2025Allow4611YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ARIANI, KADE.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
14
Examiner Affirmed
6
(42.9%)
Examiner Reversed
8
(57.1%)
Reversal Percentile
81.7%
Higher than average

What This Means

With a 57.1% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.

Strategic Value of Filing an Appeal

Total Appeal Filings
98
Allowed After Appeal Filing
32
(32.7%)
Not Allowed After Appeal Filing
66
(67.3%)
Filing Benefit Percentile
50.1%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 32.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner ARIANI, KADE - Prosecution Strategy Guide

Executive Summary

Examiner ARIANI, KADE works in Art Unit 1651 and has examined 927 patent applications in our dataset. With an allowance rate of 63.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 34 months.

Allowance Patterns

Examiner ARIANI, KADE's allowance rate of 63.9% places them in the 24% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by ARIANI, KADE receive 2.11 office actions before reaching final disposition. This places the examiner in the 56% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by ARIANI, KADE is 34 months. This places the examiner in the 42% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +49.2% benefit to allowance rate for applications examined by ARIANI, KADE. This interview benefit is in the 92% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 30.0% of applications are subsequently allowed. This success rate is in the 59% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 29.9% of cases where such amendments are filed. This entry rate is in the 43% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 88.9% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 67% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 82.3% of appeals filed. This is in the 75% percentile among all examiners. Of these withdrawals, 56.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 68.2% are granted (fully or in part). This grant rate is in the 76% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 3.5% of allowed cases (in the 81% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.3% of allowed cases (in the 53% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.